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Abstract: The anthracyclines are a group of antibiotics that are among the most potent 
chemotherapeutic agents. They are highly effective against a broad spectrum of malignancies, 
including lymphoma, gastric cancer, small cell lung cancer, sarcoma, and breast cancer. 
Unfortunately, these agents also exhibit a well-recognized cumulative-dose related cardiotoxic 
proﬁ  le that limits the extent to which they can be used safely. In clinical practice, most 
clinicians limit the cumulative dose of doxorubicin (the most widely used agent in this group) 
to 400–450 mg/m2, but considerable cardiac damage is now known to occur at cumulative 
dosages considerably below this level. Regimens using newer combinations of agents, the most 
widely studied of which is the monoclonal antibody trastuzumab, are known to augment the 
cardiotoxicity of anthracyclines. The application of nanotechnology to medicine involves the use 
of devices that will interact with the body at the molecular level. These methods can lead to target 
and tissue speciﬁ  c clinical application, often with minimal or reduced side effects. Liposomal 
preparations incorporate such technology, thereby altering some important characteristics of 
the parent compound and facilitating concentration at the tumor site. In the case of liposomal 
doxorubicin, cardiotoxicity is reduced signiﬁ  cantly. This review summarizes the important 
information on the liposomal preparation of anthracyclines.
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Introduction
The anthracyclines are a group of antibiotics that are among the most active chemothera-
peutic agents. They are highly effective against a spectrum of malignancies including 
both hematological and solid tumors including lymphoma, gastric cancer, small cell lung 
cancer, sarcoma, and breast cancer (Table 1). Some of the commonly used anthracycline 
antibiotics include doxorubicin, daunorubicin, and epirubicin. Unfortunately, these 
agents also exhibit a well-recognized cardiotoxic proﬁ  le that places limits on the extent 
to which these lifesaving agents can safely be used. In clinical practice, most clinicians 
limit the cumulative dose of doxorubicin, the most widely used agent in this group, to 
400–450 mg/m2. Thus, limiting total cumulative dose creates a dilemma of having to 
balance suboptimal oncologic treatment with a proven beneﬁ  cial therapy against that 
of the risk of cardiotoxicity. Regimens of combination chemotherapy that includes 
newer agents such as taxanes and trastuzumab are clearly effective but have resulted 
in problematic cardiotoxicity. As such, numerous techniques have been employed in 
an attempt to mitigate the cardiotoxicity of the initial anthracycline exposure, thereby 
preserving the myocardial reserves.
Moreover, as the number of long-term survivors including pediatric cancer patients 
increases, more elderly patients with pre-existing cardiovascular co-morbidities are 
given chemo-radiation therapies, and as use of combination immuno-chemotherapy 
with overlapping toxicities (eg, trastuzumab, taxanes, and anthracyclines) increase, car-
diotoxicity is increasingly becoming a very important issue today in cancer therapy.International Journal of Nanomedicine 2007:2(4) 568
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Nanotechnology can be defined as the science and 
engineering involved in the design, synthesis, characteriza-
tion, and application of materials and devices whose smallest 
functional organization in at least one dimension is on the 
nanometer scale or one billionth of a meter. It is a scientiﬁ  c 
ﬁ  eld devoted to the manipulation of atoms and molecules to 
construct miniature structures for new molecular assemblies 
at the nanometer scale size.
The application nanotechnology to medicine involves use 
of devices that will interact with the body at the molecular 
level. These methods will have high degrees of speciﬁ  city 
and can lead to target and tissue speciﬁ  c clinical applications 
with minimal side effects.
Some examples of such applications of nanotechnology 
to medicine includes development of novel drug delivery sys-
tems, chemically functionalized dendrimers that can be used as 
molecular building blocks for gene therapy agents or as mag-
netic resonance imaging (MRI) contrast agents (Silva 2004).
One of the most important clinical applications of nano-
technology appears to be in pharmaceutical development. 
Some of the emerging applications involve new approaches for 
controlled release of the drug, drug targeting, and targeting the 
organ to minimize side effects. One such example is the use of 
nanoscale polymer capsules that are designed to break down and 
release drugs at controlled rates and to allow differential release 
in certain environments, such as an acid milieu, to promote 
uptake in tumors versus normal tissues (Na and Bae 2002).
The use of nanotechnology is useful to increase the tissue 
availability of drugs with low bioavailability. Hydrophobic 
drugs such as paclitaxel or 5-ﬂ  uorouracil can be encapsu-
lated in polymers or liposomes with nanoscale cavities that 
improve drug absorption and bioavailability.
Nanoparticles in cancer may be used for various functions 
including tumor tissue and cells targeting and delivery, and 
for qualitative or quantitative in vitro detection of tumor cells 
(Brigger et al 2002).
The use of nano- and microparticle-based imaging of 
cardiovascular interventions is still in its developing phase, 
but in future may be used as a diagnostic imaging agent, 
function as a therapeutic carrier, be used as particle-mediated 
imaging of primary gene and drug delivery, and be used for 
follow-up gene therapy (Yang 2007). Hence it is not only 
applicable for diagnostic, therapeutic purposes but also to 
monitor therapeutic efﬁ  ciency after interventions performed 
to treat cardiovascular diseases.
This review summarizes important information about the 
effects of anthracyclines and the available data on liposomal for-
mulations, one of the most important strategies of cardioprotec-
tion, and expands and updates previous reviews (Ewer 2004).
Deﬁ  nition of cardiotoxicity
Antracycline-induced cardiotoxicity was ﬁ  rst described in the 
1970s. At that time anthracycline-associated cardiotoxicity was 
thought of as a cumulative dose-related form of congestive 
heart failure (CHF) that was rapidly progressive if use of the 
agent was continued. Von Hoff et al (1979) provided important 
initial insight regarding clinically manifested CHF. Increased 
awareness of sub-clinical cardiac impairment resulting from 
these agents has led to improved screening as well as a better 
perspective of the inherent toxicity of these agents. Today’s 
deﬁ  nition has expanded from the clinical events of cardiac 
failure to include a wide spectrum of predeﬁ  ned laboratory 
values even when patients may be asymptomatic. These 
include histological changes (Billingham and Bristow 1984) in 
the cardiomyocytes (Table 2), and changes in left ventricular 
ejection fraction (LVEF) based on either radionuclide ventricu-
lography (Schwartz et al 1987) (RNVG) or two-dimensional 
(2D)-echocardiography (Stoddard et al 1992). Even transient 
changes previously thought to be not of any major clinical 
signiﬁ  cance, eg, daunorubicin-induced myocarditis/pericar-
ditis (Topalov et al 1981; Gaudin et al 1993) will now be 
considered as anthracycline-induced cardiomyopathy. The 
general consensus is that a decrease in LVEF by more than 
20 percentage points to a value  50%, a decrease in LVEF by 
more than 10 percentage points to a value  50%, or clinical 
manifestations with signs and symptoms of CHF constitute 
cardiotoxicity. Others have combined these criteria to deﬁ  ne 
cardiotoxicity as a decrease in LVEF by more than 10 points 
to a ﬁ  nal value of  50% (Ganz et al 1993).
Incidence of cardiotoxicity
with conventional anthracyclines
Using the reﬁ  ned criteria, in large clinical trials, approxi-
mately one in four patients experienced congestive heart 
Table 1 Malignancies commonly treated with anthracyclines
Malignant lymphoma
Soft tissue and bone sarcoma
Acute lymphoblastic leukemia
Ovarian carcinoma
Breast cancer
Neuroblastoma
Transitional cell bladder carcinoma
Thyroid carcinoma
Gastric carcinoma
Wilm’s tumor
Bronchogenic carcinoma (small cell)
AIDS-related Kaposi’s sarcomaInternational Journal of Nanomedicine 2007:2(4) 569
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failure when the cumulative dose of doxorubicin exceeded 
500 mg/m2, nearly 50% had cardiac events above 600 mg/
m2, and nearly all patients had cardiotoxicity above 800 
mg/m2. The incidence of clinical cardiac failure increases 
precipitously above 550 mg/m2 (Von Hoff et al 1979) with 
the majority developing cardiomyopathy within the ﬁ  rst 
year of completion of treatment. More recent data, however, 
suggest that cardiomyopathy not only develops at a much 
lower cumulative dose than previously thought, but it may 
also manifest even years after treatment, especially in pedi-
atric oncology survivors (Lipshultz et al 1991; Steinherz 
et al 1991; Hequet et al 2004). An analysis by Steinherz 
et al (1991) of 201 long-term childhood cancer survivors 
4–20 years after completion of anthracycline-based chemo-
therapy showed almost a quarter of the patients remain at risk 
for developing cardiomyopathy even years after exposure. 
Cardiac biopsy as well as newer imaging techniques suggest 
that cardiac damage almost certainly takes place from the 
onset of anthracycline exposure irrespective of its detection 
by conventional non-invasive cardiac parameters.
Risk factors for anthracycline-
induced cardiotoxicity
Complete details regarding the risk factors are beyond the 
scope of this review. In brief, the recognized risks besides 
the cumulative anthracycline dose include age (elderly and 
young), mediastinal irradiation or radiotherapy to the left 
chest, other cardiac risk factors such as hypertension, female 
gender (especially in the pediatric population), previous 
exposure to any anthracycline, coadministration of other 
anticancer drugs, and methods of administration (bolus 
vs protracted infusion) (Von Hoff et al 1979; Steinherz 
et al 1991; Anon 2000; Hequet et al 2004). Other natural 
phenomena in these immunocompromised populations such 
as infections that involve the myocardium may constitute 
sequential stresses that when superimposed on an impaired 
myocardium may result in life-threatening or disabling 
heart failure (Ali et al 1994). Given that the two leading 
causes of death in the United States are cardiovascular 
diseases and malignant neoplasms (Anon 2006; Banks et al 
2006), in an increasingly aging population, patients with 
cancer are ever more likely to have other co-morbidities, 
in particular diseases of the cardiovascular system, 
making them more susceptible to chemotherapy-induced 
cardiomyopathy. Additionally, cardiac risk factors such 
as hypertension, hyperlipidemia, and diabetes (Zambetti 
et al 2001), although unrelated to anthracycline toxicity, 
may also contribute to the progression of cardiac damage 
and clinical cardiotoxicity.
Pathology of anthracycline-induced 
cardiotoxicity
Early morphologic changes include cytoplasmic vacuoliza-
tion and myoﬁ  brillar loss of myocytes caused by dilatation 
of the sarcoplasmic reticulum (Figure 1, Table 2). In more 
advanced cases, such cellular changes lead to cardiac 
remodeling and eventually to left ventricular failure with 
increased mortality (Billingham et al 1978; Von Hoff 
et al 1979). The mechanism of conventional doxorubicin-
induced myocardial damage is not exactly known but is 
believed to involve production of free radicals that induce 
peroxidation of myocyte membranes and subsequent 
inﬂ  ux of intracellular calcium (Andrieu-Abadie et al 1999; 
Falcone et al 1998). One source of such reactive oxygen 
intermediates is the formation of conventional doxorubicin-
iron complexes in mitochondrial membranes that may 
Table 2 Morphologic grading systems for anthracycline cardiotoxicity
Grade  Billingham scoring system (Billingham et al 1978)   Mackay scoring system (Mackay et al 1994; Ewer et al 1984)
  morphologic characterics Vacuoles  Myoﬁ  brillar dropout  Necrosis
0  Normal myocardial ultrastructural morphology
0.5  Not completely normal but no evidence 
 of  anthracycline-speciﬁ  c damage   4 0  1
1  Isolated myocytes affected and/or early myocﬁ  briller loss; 
 damage  to   5% of all cells  4–10   3 1
1.5  Changes similar to grade 1 except damage involves 
  6%–15% of all cells   10 3–5   2
2  Clusters of mycocytes affected by myoﬁ  brillar loss and/or 
  vacuolization, with damage to 16%–25% of all cells  any number  6–8  2–5
2.5  Many mycocytes (26%–35% of all cells) affected by vacuolization 
 and/or  myoﬁ  brillar loss  (The grade of 2.5 is not included in the Mackay grading system)
3  Severe, diffuse myocyte damage ( 35% of all cells)  any number   8   5International Journal of Nanomedicine 2007:2(4) 570
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lead to increased inner membrane permeability in heart 
mitochondria as a result of increasing the sensitivity of a 
Ca2+ dependent-pore of the inner mitochondrial membrane 
to calcium, leading to dissipation of membrane potential 
and release of pre-accumulated Ca2+ (Al-Nasser 1998). 
Mitochondrial dysfunction correlated with morphologic 
changes seen in cumulative and irreversible cardiotoxicity 
may also be caused by accumulation and persistence of 
8-hydroxyguanosine adducts in cardiac mitochondrial DNA 
(Serrano et al 1999). Additionally, impaired sequestration 
of intracellular free calcium ions in individual myocytes as 
a result of drug exposure may cause impairment of essential 
fatty acid metabolism (Bordoni et al 1999) and diastolic 
dysfunction (Maeda et al 1998). Since high cardiac tissue 
levels of doxorubicinol, a metabolite of the conventional 
doxorubicin, are associated with both functional and 
morphologic changes consistent with the anthracycline 
cardiomyocyte injury, it may be possible to prevent the 
reductase pathway leading to doxorubicinol production, 
thereby decreasing cardiotoxicity without impairing the 
therapeutic efﬁ  cacy of anthracyclines (Minotti et al 2001). 
The cytotoxic effect of anthracyclines on cardiomyocytes 
is generally thought to be irreversible and cumulative dose 
related. Biopsy data as well as the shape of the dose-response 
curve provide strong evidence that damage takes place from 
the time of the initial exposure, despite the fact that cardiac 
reserves prevent clinical recognition until sufﬁ  cient damage 
has taken place to the extent that the compensatory reserve 
of the heart is exceeded.
Clinical relevance 
of cardiomyopathy
The reported incidence of anthracycline-associated 
cardiomyopathy varies widely depending on the way it 
is ascertained, the setting in which it is studied, and the 
underlying risk of the patient population. The earliest and 
the most often cited study was based on a retrospective 
analysis of patients enrolled in phase II studies of conven-
tional doxorubicin (Von Hoff et al 1979). Cardiomyopathy 
had not been previously studied and was to some extent 
the only endpoint recorded in the medical records at the 
time was clinically manifested heart failure. From a curve 
relating cumulative dose to the incidence of CHF, it was 
estimated that after 728 mg/m2 the probability of develop-
ing CHF was in excess of 20%.
However, with advanced imaging techniques and 
close patient monitoring, the incidence of any form of 
cardiomyopathy using serial evaluations of left ventricular 
ejection fraction, may be considerably higher than was reported 
initially. A pooled analysis of 630 patients who underwent 
serial evaluations of cardiac function during conventional 
doxorubicin treatment in three controlled trials reported 
A B
Figure 1 Electron micrographs showing examples of representative ﬁ  eld of a high-grade biopsy (Billingham score of 3.0) obtained from a solid-tumor patient who received 
more than 400 mg/m2 conventional doxorubicin. Severe diffuse damage to  35% of all cells was seen. Necrotic cell is shown with extensive myoﬁ  brillar loss (A). Another 
cell is seen with extensive vacuolization (B, center). Magniﬁ  cation is indicated by a bar in each frame. (Micrographs courtesy of Gerald Berry MD, Stanford University School 
of Medicine (Ewer et al 2004)).International Journal of Nanomedicine 2007:2(4) 571
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a CHF incidence of 26% after a cumulative dose exceeding 500 
mg/m2, 48% for a cumulative dose exceeding 600 mg/m2, 
and 100% above 800 mg/m2 (Swain et al 2003). Subclinical 
evidence of cardiomyopathy may occur at lower cumulative 
doses, as suggested by a study of 141 patients who received 
conventional doxorubicin for lymphoma (Hequet et al 
2004); 28% of patients had subclinical cardiomyopathy 
(deﬁ  ned as left ventricular fractional shortening  25%), 
including 25% of patients who received a cumulative dose 
300 mg/m2. In one study of patients with breast or lung 
cancer who were treated with a combination regimen that 
included cyclophosphamide, CHF was observed in more 
than 20% of those given a cumulative dose of 500 mg/m2 
(Shapiro et al 1998).
Studies where the incidence of CHF was reported to be 
very low (from 0.2% to 0.9%) used conventional doxorubicin 
as part of a combination regimen and were used as adjuvant 
therapy for early breast cancer (Shapiro and Recht 2001). In 
these studies, the cumulative dose of conventional doxorubicin 
rarely exceeded 300 mg/m2 and was usually 240 mg/m2. 
However, in subsequent controlled studies in women with 
breast cancer, the incidence of CHF increased to 4.7% at a 
cumulative dose of 400 mg/m2, and 26% at cumulative doses 
of 550 mg/m2 (Swain et al 2003). Therefore, while patients 
may respond favorably to initial anthracycline therapy up to 
cumulative doses of less than 300 mg/m2, extra precaution 
is warranted because of heightened risk of cardiotoxicity 
before additional conventional anthracycline treatment is 
started when relapse occurs. Alternative treatments that 
have comparable or better efﬁ  cacy but yet have a lower 
risk of cardiotoxicity may be considered in patients with 
anthracycline-sensitive tumors.
Cardiotoxicity secondary to treatment with conventional 
doxorubicin remains a serious problem in survivors of pediatric 
malignancy long after the cancer has been cured (Lipshultz 
2006). In a cohort of 607 children, 2.8% of patients treated 
with a median anthracycline dose of 301 mg/m2 developed 
CHF after a median follow-up period of 6.3 years (Kremer et al 
2001). It is estimated that 5% of patients will develop CHF 
within 15 years after anthracycline treatment. For children 
receiving a cumulative dose of more than 300 mg/m2, the 
relative risk of developing CHF was 11.8-fold greater than for 
those exposed to less than 300 mg/m2 (Lipshultz 2006).
Potentiation of cardiotoxicity 
in combination regimens
Use of trastuzumab either concomitantly or sequentially fol-
lowing anthracycline treatment may potentiate conventional 
anthracycline-induced cardiotoxicity (Valagussa et al 2001; 
Genentech 2003), or, more commonly, represents a sequential 
stress to a previously damaged myocardium. In a pivotal trial 
to obtain regulatory approval for the use of trastuzumab, 
patients with metastatic breast cancer who had not previ-
ously been treated with adjuvant conventional doxorubicin, 
a signiﬁ  cantly higher incidence of cardiotoxicity was noted 
in the trastuzumab arm, whether this was measured as “any 
form of cardiotoxicity” or only grade III/IV cardiotoxicity. 
Several clinical trials are under way to determine if sequential 
administration of trastuzumab and conventional doxorubicin 
is associated with similar chemotherapeutic activity but less 
cardiotoxicity than concurrent use (Wolff 2003). One such 
recently published large randomized trial, National Surgical 
Adjuvant Breast and Bowel Project trial B-31 (Tan-Chiu et al 
2005), compared doxorubicin and cyclophosphamide (AC) 
followed by paclitaxel with AC followed by paclitaxel plus 52 
weeks of trastuzumab beginning concurrently with paclitaxel 
in patients with node-positive, HER2-positive breast cancer. 
If symptoms suggestive of CHF developed, source documents 
were blindly reviewed by an independent panel of cardiolo-
gists to determine whether criteria were met for a cardiac 
event, which was deﬁ  ned as New York Heart Association 
class III or IV CHF or possible/probable cardiac death. Among 
patients with normal post-AC LVEF who began further treat-
ment, 5 of 814 control patients subsequently had conﬁ  rmed 
cardiac events (4 CHFs and 1 cardiac death) compared with 
31 of 850 trastuzumab-treated patients (31 CHFs and no 
cardiac deaths). The difference in cumulative incidence at 3 
years was 3.3% (4.1% for trastuzumab-treated patients minus 
0.8% for control patients; 95% CI, 1.7%–4.9%). CHFs were 
more frequent in older patients and patients with borderline 
post-AC LVEF. Fourteen percent of patients discontinued 
trastuzumab because of asymptomatic decreases in LVEF; 
4% discontinued trastuzumab because of symptomatic car-
diotoxicity. While the sequential use of trastuzumab following 
anthracycline administration is increasingly accepted, many 
clinicians feel that the concomitant use of this combination 
increases the risk sufﬁ  ciently so that such regimens should 
not be routinely implemented.
There have been inconsistent reports of high incidence of 
cardiotoxicity with combinations of conventional doxorubicin 
and paclitaxel (AT) (Gianni et al 1995; Dombernowsky et al 
1996; Moore et al 1998; Valagussa et al 2001). In the trials 
with the highest incidence of cardiotoxicity, paclitaxel was 
given as a 1- or 3-hour infusion in close approximation to the 
administration of conventional doxorubicin as a bolus or short 
infusion. The incidence of cardiomyopathy was relatively International Journal of Nanomedicine 2007:2(4) 572
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small as long as the cumulative dose of conventional 
doxorubicin in combination with paclitaxel was less than 
360 mg/m2. Cardiotoxicity from the AT combination was ﬁ  rst 
reported from a trial in which 35 women with breast cancer 
received conventional doxorubicin 60 mg/m2 15 minutes 
before or after escalating doses of paclitaxel 125–200 mg/m2. 
Five-year follow-up of 141 patients from this trial and 2 other 
similar trials identiﬁ  ed 7 cases of CHF (5%): 1 case after a 
cumulative conventional doxorubicin dose of 120 mg/m2 
and 6 after 360 mg/m2 (Valagussa et al 2001). Another 11 
patients had LVEFs of  50% that returned to normal with 
longer follow-up. The actuarial cumulative risk of CHF was 
30% overall, but was only 4% in those who received less than 
360 mg/m2 of conventional doxorubicin.
This increased risk of cardiotoxicity with the combination 
therapy may be attributable to the pharmacokinetic interfer-
ence between paclitaxel and doxorubicin which may result 
in nonlinear plasma disposition of doxorubicin and increased 
plasma concentrations of doxorubicin and doxorubicinol 
(Gianni et al 1997). In a retrospective analysis of 657 patients 
treated with AT in 10 trials performed at multiple centers, 
4.7% developed CHF (Gianni et al 2001), although the inci-
dence of CHF in the patients treated with AT was not very 
different from that of a single-agent conventional doxorubicin 
at cumulative doses below 340–380 mg/m2.
Mechanism of cardiac-sparing effect 
of liposomal anthracyclines
Nonpegylated liposomes generally extravasate in areas of 
pathology where capillaries are disrupted by inﬂ  ammation or 
tumor growth and in organs lined with fenestrated endothelial 
barriers (ones without tight junctions such as the liver, spleen, 
and bone marrow) (Gabizon et al 1997; Schiffelers et al 2000). 
Since the myocardium is supplied by vessels with tight junc-
tions (Tardi et al 1996), liposomal encapsulation would be 
expected to shift doxorubicin away from myocardial tissue, 
while maintaining tumor exposure. This tissue distribution pat-
tern is supported by various preclinical and clinical pharmaco-
logic studies of class I to III liposomal doxorubicin formulations 
summarized here, although the rapid clearance by the reticu-
loendothelial system of these early generations of liposome 
formulations may reduce the liposome fraction deposited in the 
tumor. Furthermore, pegylated liposomal doxorubicin (PLD) is 
preferentially taken up by tumor compared with normal cells 
in patients with breast and other solid cancers.
Encapsulation of doxorubicin by pegylated liposomes, 
causes impairment of its uptake by the reticulo-endothelial 
system, which results in the prolongation of the serum 
half-life to around 50 hours compared with 10 minutes 
for the free drug (Berry et al 1998). Due to an additional 
polyethylene glycol layer, the PLD also has lower uptake 
by the mononuclear phagocyte system, resulting in a greater 
plasma half-life relative to other liposomal anthracyclines. 
As a result, pegylated liposome formulations remain in 
circulation to a much longer extent, entering tumors through 
the leaky tumor vasculature in high levels, and to a much 
lesser extent in normal tissues outside the reticuloendothelial 
system (Gabizon et al 2003). Indeed, drug levels measured in 
heart muscle after correction for blood content are lower for 
PLD than for conventional doxorubicin, more so when peak 
concentrations are compared (Papahadjopoulos et al 1991). 
Moreover, because the interstitial spaces in the myocardium 
are well drained by lymphatics (Eliskova and Eliska 1989), 
much of the drug carried into this compartment by extravasated 
liposomes may pass through the tissue spaces and enter 
lymphatic flow in encapsulated form without releasing 
doxorubicin. Drug remaining encapsulated while passing 
through the myocardium would not become bioavailable and 
thus would not be expected to contribute to cardiac muscle 
cell toxicity. Another likely mechanism by which liposomal 
doxorubicin may attenuate cardiotoxicity is simply by blunting 
the high plasma peak levels of free drug associated with bolus 
injections of conventional doxorubicin that correlate with 
cardiotoxicity (Lyass et al 2000).
Monitoring cardiotoxicity
Cardiotoxicity of conventional doxorubicin remains a real 
issue despite the introduction of cardioprotectants. Liposomal 
formulations have reduced these concerns with regard to the 
treatment of some forms of malignancy; this is especially true 
with regard to ovarian and breast cancer (O’Brien et al 2004; 
Mrozek et al 2005). Because of the signiﬁ  cant heterogene-
ity of anthracycline toxicity, monitoring for early detection 
before the clinical onset of cardiomyopathy is of paramount 
importance in the management of patients receiving anthra-
cycline based chemotherapy. This may lead to appropriate 
intervention when the need arises (Ewer et al 2005).
Endomyocardial biopsy
Billingham et al (1978) developed a histologic scoring system 
based on endomyocardial biopsy that displays higher sensitivity 
for early cardiac damage and has shown good correlation 
with the cumulative dose of anthracyclines (Table 2). 
However, it is an invasive test with its attendant morbidity- 
thus making it impractical for day to day monitoring. The 
histologic changes do not correlate with subsequent risk of International Journal of Nanomedicine 2007:2(4) 573
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CHF, neither does it provide data on myocardial function 
or the clinical state of the patient. Therefore, although 
traditionally considered as the “gold standard” test for the 
evaluation of anthracycline cardiomyopathy, other tests like 
radionuclide ventriculography or echocardiography are used 
more commonly in the evaluation of cardiotoxicity.
Radionuclide ventriculography (RNVG)
A retrospective series, reviewed by Schwartz et al (Schwartz 
et al 1987) on 1487 doxorubicin-treated patients investigated 
over a 7-year interval using RNVG suggests that serial 
RNVG is an appropriate and cost-effective approach for the 
prediction and prevention of impending CHF. Assessment 
of serial LVEF and assessment of regional wall motion by 
RNVG are now an integral part of monitoring cardiotoxicity. 
This accurate and highly reproducible test identiﬁ  es high risk 
patients for developing doxorubicin cardiomyopathy includ-
ing: (1) those with a decline of more than 10 ejection fraction 
percentage points from normal baseline to a ﬁ  nal value of 
less than 50%; (2) those with a baseline ejection fraction 
of less than 50%. or (3) those receiving a total doxorubicin 
dose of 450 mg/m2.
2D-echocardiography
This is a completely noninvasive test, highly portable, 
does not utilize ionizing radiation, and is readily available. 
Although extensively used in clinical practice, monitoring 
changes in systolic function alone has not achieved the 
desired goal of early detection of subclinical cardiac 
damage. In addition to the parameters measured by RNVG 
(systolic function and wall motion) echocardiography also 
incorporates the diastolic function which some consider to be 
a more accurate predictor of early cardiotoxicity (Stoddard 
et al 1992; Ganz et al 1993) possibly allowing a modiﬁ  cation 
of treatment strategies to protect the vulnerable myocardium. 
Indeed, such pre-emptive treatment could contribute to a 
signiﬁ  cant reduction in chemotherapy related cardiotoxicity. 
Complete details regarding the methods of performing these 
tests are beyond the scope of this review.
Antimyosin antibody scintigraphy
Radio labeled antimyosin antibody scintigraphy is a very 
sensitive test for the monitoring of anthracycline cardiotoxic-
ity. The myocardial uptake of antimyosin antibody is highly 
correlated with the severity of myocardial injury. In fact at 
a cumulative dose of 240–300 mg/m2 doxorubicin, almost 
all patients will exhibit a positive result (Valdes Olmos 
et al 2002) making it an impractical test to be applied and 
interpreted routinely.
Biomarkers for detection of cardiotoxicity
Troponin levels correlate well with histologic changes 
related to early cardiomyocyte damage in acute myocardial 
infarction (Jaffe et al 2006). Similarly, monitoring with 
brain natriuretic peptides (BNP) has been used to monitor 
patients with CHF (Price et al 2006). However, notwith-
standing some indication that these markers are elevated 
in patients who have experienced anthracycline exposure, 
the tests, as utilized at this time neither have the sensitivity 
nor speciﬁ  city to clearly predict a subgroup of patients that 
either should avoid these agents or who should have alter-
nate forms of cardiac monitoring (Nousiainen et al 1999; 
Gaze and Collinson 2005; Polena et al 2005). Additionally, 
troponins and BNP may be elevated in the cancer patient 
for reasons that have not yet been fully elucidated, or to 
conditions that occur more frequently in the cancer patient 
such as ischemic heart disease (Jaffe et al 2006), pulmonary 
embolism (Tulevski et al 2006), and sepsis (Favory and 
Neviere 2006).
Strategies to minimize cardiotoxicity
Strategies to minimize cardiotoxicity include the use of pro-
tective agents such as dexrazoxane (Silber 2004), different 
preparations of anthracyclines, and alternative scheduling 
techniques. Readers are referred to the previous reviews 
where these have been described in details (Iarussi et al 
2001). Liposomal formulations of conventional doxorubicin 
represent one of the recent approaches to ameliorating and or 
preventing the problem of anthracycline cardiotoxicity.
Liposomal anthracyclines
There are various formulations of liposomal anthracy-
clines for human use, including liposomal daunorubicin 
(DaunoXome®), liposomal doxorubicin (D-99, Myocet®), 
and PLD (Doxil® and Caelyx®). However, all conventional 
or pegylated liposomes are not the same. The ratio and the 
composition of various lipids can be modiﬁ  ed for different 
liposomal compounds and the percentage of polyethylene 
glycol (PEG) added to the liposome can also be different, 
yielding varied pharmacodynamic properties.
The introduction of targeted therapy in addition to 
conventional chemotherapy for the management for various 
cancers has improved the outlook for patients. More and 
more methodology is being devised to provide relatively safer 
drugs. One such technique is the encapsulation of doxorubicin 
in PEG-coated liposomes (Vail et al 2004). Liposomes are 
microscopic vesicles consisting of a phospholipid bilayer that 
when placed around an active drug alters the pharmacologic International Journal of Nanomedicine 2007:2(4) 574
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and pharmacokinetic proﬁ  les of conventional anthracycline. To 
protect the molecule further from phagocytosis, a polyethylene 
glycol (PEG) coating may be used around the liposome bilayer 
by a process known as pegylation, and the new compound is 
called a pegylated liposomal anthracycline. Another rationale 
of encapsulating doxorubicin within liposomes is to allow the 
sequestration of the drug from organs such as the heart and 
gastrointestinal tract that have tight capillary junctions, while 
enhancing delivery of the cytotoxic agent to tumor sites lined 
by compromised vasculature (Hobbs et al 1998). As such the 
drug delivery to the tumor is enhanced, it results in increased 
concentration of the drug at the tumor site. This also confers 
a longer half-life, smaller volume of distribution, and reduced 
clearance of the drug at the tumor site, all resulting in a greater 
efﬁ  cacy (Allen and Martin 2004). On the basis of these pharma-
cokinetic principles alone, liposomal doxorubicin has potential 
applications to treat a variety of cancers either alone or as part 
of combination therapy (Vaage et al 1994).
Conventional doxorubicin enters tissues as a concentrated 
pulse. Pegylated liposomes, on the other hand, cause doxoru-
bicin to be slowly released into these tissues over several days, 
and change the biodistribution of the drug away from normal 
tissues. Thus the proportion of doxorubicin that is bioavailable 
at the tumor site at any one time is several times higher than 
it is in normal tissues (Vaage et al 1994). Since only the free 
doxorubicin that is released from the liposome is bioavailable 
doxorubicin concentration does not exceed that of conventional 
doxorubicin except in the sites with extensive reticuloendothe-
lial systems where intact liposomes accumulate (Vaage et al 
1994; Hobbs et al 1998; Allen and Martin 2004; Vail et al 
2004). Since doxorubicin in the plasma remains encapsulated 
in liposomes, the plasma level of free doxorubicin that is 
responsible for toxicity of non-tumor related organs including 
the myocardium remains very low following administration 
of PLD. Thus, toxicity normally associated with conventional 
doxorubicin is signiﬁ  cantly decreased. A detailed review of 
the structure, pharmacokinetic, and pharmacodynamics of 
these agents have been discussed elsewhere (Vail et al 2004), 
and is beyond the scope of this review. Moreover, prolonged 
half-life and targeted delivery to the tumor makes it possible 
to use less frequent dosing without diminishing the efﬁ  cacy, 
thereby potentially enhancing tolerability and convenience of 
therapy (Vaage et al 1994).
Preclinical treatment models 
of PLD
PLD and other pegylated liposomal formulations of anthra-
cycline have been evaluated in numerous animal models. In 
preclinical models, pegylated liposomal formulations that 
differ either in the lipid make-up of the liposome or the amount 
of   PEG on the surface of the liposome, were shown to be 
equally effective against low- and high-growth fraction tumors 
(Vail et al 2004). It resulted in remission and cure against a wide 
variety of solid cancers including malignancies of the breast, 
lung, ovaries, prostate, colon, bladder, and pancreas, as well 
as against hematologic malignancies including lymphoma, 
and myeloma (Gabizon et al 2006). As adjuvant therapy, it 
was also noted to be equally effective. Additionally, liposomal 
anthracyclines cross the blood-brain barrier to induce remis-
sion in malignancies of the central nervous system (Saito et al 
2004). It also showed additive and synergistic effects when 
used in combination with vincristine or trastuzumab (Bernard-
Marty et al 2006). An interaction between the liposome and 
P-glycoprotein function, as well as increased concentrations 
at tumor site, might even overcome multidrug resistance in 
selected cases. Several investigations are underway following 
these studies which provided preliminary evidence of its many 
potential uses. A summary of some of the more important 
preclinical data follows.
Colon cancer
Tumor burden of doxorubicin-resistant C26 mouse colon can-
cer in Balb/c male mice treated with PLD was markedly inhib-
ited as opposed to no signiﬁ  cant inhibition of tumor growth 
with conventional doxorubicin on days 10, 17, and 24 after 
tumor inoculation (Mayhew et al 1990; Huang et al 1992).
Breast cancer
PLD is more effective at inhibiting the growth of xeno-
grafts initiated by subcutaneous inoculation of BT474 and 
MDA MB453 human breast cancer cell lines or primary 
human breast cancer, B585, in nude mice compared with 
the same dose or a higher dose of conventional doxorubi-
cin (Colbern et al 1998). PLD treatment also signiﬁ  cantly 
increased the mean survival time of mice with MC2 and 
MC65 tumors, 8 weeks after tumor implantation (Vaage 
et al 1992).
Ovarian and other cancers
Similar anti-tumor activity of PLD and signiﬁ  cant increases 
in mean survival time were also evident in nude mice 
implanted either subcutaneously or intraperitoneally (IP) with 
the human ovarian carcinoma HEY (Vaage et al 1993), lung 
cancer (Colbern et al 1999), leukemia (Working and Dayan 
1996), lymphoma (Cabanes et al 1998), and in prostate cancer 
(Vaage et al 1994). However, PLD did not perform as well as International Journal of Nanomedicine 2007:2(4) 575
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conventional doxorubicin in orthotopic xenografts of human 
bladder cancer (Mazurchuk et al 1997).
Cardiotoxicity in preclinical trials
In general, toxicities observed in animals with PLD treat-
ment are similar to but less severe than those of conven-
tional doxorubicin with several important exceptions, most 
notably cardiotoxicity (Working and Dayan 1996). At 
identical cumulative doses of conventional doxorubicin, 
both the incidence and severity of cardiotoxicity were 
either substantially decreased or entirely absent in rats, 
rabbits, and dogs administered PLD (Vaage et al 1994; 
Cabanes et al 1998). The decreased cardiotoxicity may 
be related to the decreased peak concentration of free, 
non-liposomal doxorubicin in the plasma and tissues of 
PLD-treated animals.
Preclinical studies
In preclinical studies, liposomal formulations have been 
classiﬁ  ed in different ways depending on the lipid make-up 
of the liposome or the amount of PEG on the surface of the 
liposome; they have been classiﬁ  ed as classes I–IV.
Class Ia/Ib liposomal doxorubicin
Rahman and colleagues have extensively studied the 
pharmacological, toxicological, and therapeutic effects 
doxorubicin entrapped in cardiolipin liposomes including 
comparing cardiotoxicity of a type Ia liposomal doxoru-
bicin with that of conventional doxorubicin in groups of 
mice (Rahman et al 1980, 1982, 1984, 1985; Herman et al 
1983). At a dose of 4 mg/kg, the peak cardiac concentration 
achieved in 30 minutes following conventional doxorubicin 
administration was signiﬁ  cantly higher than that with the 
drug entrapped in cardiolipin liposomes, resulting in a 
signiﬁ  cantly lower histopathologic lesions in cardiac tissue 
of mice as determined by electron microscopy (Rahman 
et al 1980, 1984, 1985; Herman et al 1983). Gokhale et al 
(1996) reported an improved formulation using synthetic 
cardiolipin in 1996 – class Ib – which despite achieving a 
44-fold higher plasma drug levels showed levels in cardiac 
tissue at least 2-fold lower than that observed with conven-
tional doxorubicin in mice.
Class II liposomal doxorubicin
In one representative study of the class II liposomal 
doxorubicin formulation, the cardiac toxicity of conventional 
doxorubicin was compared with that of doxorubicin encap-
sulated in liposomes incorporating phosphatidylcholine, 
phosphatidylserine, both negatively charged, naturally 
occurring phospholipids, and cholesterol (Storm et al 
1989). After 5 daily doses of 2.0 mg/kg, a much lower 
doxorubicin concentration was found in cardiac tissue with 
the administration of the class II liposomal formulation 
relative to conventional doxorubicin given either by bolus 
or infusion. Other studies of class II liposomal formulations 
supported these observations (Gabizon et al 1982, 1983, 
1986). The histopathology scores of myocardial lesions based 
on the method of Bertazzoli et al (Solcia et al 1981) were 
signiﬁ  cantly lower for liposomal doxorubicin. Moreover, 
there was a trend to improvement in the off-therapy period 
in the liposomal doxorubicin treated groups.
Class III liposomal doxorubicin
Preclinical studies showed that administration of class III 
doxorubicin liposomes reduces the peak distribution of the 
drug to the heart but effectively delivers doxorubicin to 
tumors (Balazsovits et al 1989; Kanter et al 1993). None 
of the dogs treated with non-PLD (NPLD) had lesions sug-
gestive of cardiomyopathy compared to moderate to severe 
vacuolization of myocardial tissue in those that received 
conventional doxorubicin.
Class IV PLD
Dogs treated with conventional doxorubicin up to a 
cumulative dose of 10 mg/kg showed vacuolization and 
myoﬁ  brillar loss in the myocardium, while no histologic 
evidence of cardiotoxicity was seen in dogs exposed to PLD 
(Working et al 1999) either 1 or 5 weeks after treatment. 
In rabbits, progressive cardiomyopathy was seen in both 
conventional and liposomal doxorubicin treatment groups, 
but the cardiomyopathy was more frequent and severe with 
conventional doxorubicin than with PLD.
Clinical trials with liposomal 
anthracyclines
Class I and II liposomal doxorubicin
In a phase II clinical study 20 patients with advanced breast 
cancer were treated with class Ia liposome-encapsulated 
doxorubicin with a cumulative dose greater than 500 mg/m2. 
Five of these 20 underwent endomyocardial biopsies 4 
demonstrating no histologic change (Billingham grade 0) 
and 1 showing mild myoﬁ  brillar loss and dilatation of the 
sarcoplasmic reticulum involving less than 5% of cardiac 
myocytes in. The cumulative dosage for these patients was 
up to 750 mg/m2. Even those who had decreases in LVEF 
(2) had no clinical evidence of CHF and a Billingham International Journal of Nanomedicine 2007:2(4) 576
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endomyocardial biopsy score of 0.9. Class II liposomal 
doxorubicin formulations were used in two pilot clinical trials 
but the cumulative doses were too low to assess cardiotoxicity 
(Gabizon et al 1989; Owen et al 1992).
Class III liposomal doxorubicin
The first of several large randomized trials involved 
224 women with metastatic breast cancer exposed to equal 
dosages and schedule of NPLD or conventional doxorubi-
cin (Harris et al 2002). There was a signiﬁ  cant difference 
in favor of the NLPD in the percentage of patients with 
protocol-deﬁ  ned cardiotoxicity and the number of patients 
with CHF despite similar efﬁ  cacy of the regimens. The haz-
ard ratio for cardiotoxicity with conventional doxorubicin 
compared with NPLD was 3.56 (p = 0.0001) (Figure 2A). 
Cardiac biopsies in 36 of these patients documented a 
Billingham score  2.5 in 70% of the patients treated with 
conventional doxorubicin compared to 5% of the patients 
treated with NPLD (FDA 2002).
Cardiotoxicity ﬁ  ndings of a randomized clinical trial in 
patients with breast cancer using NPLD in combination with 
cyclophosphamide 600 mg/m2 every 3 weeks (MC regimen) 
(Batist et al 2001) were compared with the same doses in the 
conventional doxorubicin plus cyclophosphamide regimen 
(AC regimen). The efﬁ  cacy of the two combinations was 
similar but protocol-deﬁ  ned cardiotoxicity was signiﬁ  cantly 
less common with the MC regimen. Patients were 80% less 
likely to develop cardiotoxicity while on MC compared with 
AC (hazard ratio 4.8) and the time to a cardiac event was 
signiﬁ  cantly longer for MC treatment (Figure 2B). There 
was a gradual decrease in median LVEF as the cumulative 
dose of NPLD increased, but this too was less marked than 
was seen with conventional doxorubicin. In another study, no 
signiﬁ  cant differences were noted in the incidence of cardio-
toxicity between patients treated with NPLD 75 mg/m2 plus 
cyclophosphamide 600 mg/m2 when compared with the same 
doses of epirubicin and cyclophosphamide. Taken together, 
the randomized trials comparing similar doses of NPLD and 
conventional doxorubicin, either alone or in combination, 
provide strong evidence for the principle that liposomal 
encapsulation of conventional doxorubicin results in a sub-
stantial reduction, but not total eradication, of cardiotoxicity 
(Batist et al 2000).
Anthracyclines in high risk cardiac 
patients
In a subset analyses in 68 high risk cardiac patients (because 
of either prior conventional doxorubicin exposure or other 
risk factors for cardiac disease) performed on pooled 
data from the randomized trials (Batist et al 2000; Winer 
et al 2000), predeﬁ  ned cardiotoxicity was documented in 
22% of the patients receiving NPLD and 39% receiving 
conventional doxorubicin despite being exposed to a greater 
cumulative anthracycline dose on the NPLD arm (median, 
308 mg/m2; n = 32) than the conventional doxorubicin arm 
(median, 225 mg/m2; n = 36). CHF was seen in 3% and 
8%, respectively and the cumulative anthracycline dose 
before a cardiac event was 780 and 570 mg/m2 (p = 0.001) 
for NPLD and conventional doxorubicin. Using the same 
database, Winer et al (2000) looked at a subset of patients 
at increased risk of cardiotoxicity as a consequence of 
age (mean 65 years), prior mediastinal/chest irradiation, 
prior adjuvant conventional doxorubicin (240 mg/m2) or 
prior cardiac disease (Winer et al 2000). Cardiotoxicity 
occurred in 10% of those who received NPLD and 26% of 
those who received conventional doxorubicin (p = 0.003). 
CHF was seen in 1% and 7% and the cumulative lifetime 
doxorubicin dose was 785 and 570 mg/m2 (p = 0.0001) 
respectively in the NPLD and conventional doxorubicin 
arms (Winer et al 2000).
NPLD: combinations with other 
cardiotoxic agents
In addition to cumulative-dose concerns, the cardiotoxicity of 
conventional anthracyclines is enhanced by coadministration 
of other cardiotoxic agents such as paclitaxel or trastuzumab. 
However, several small phase I/II trials assessed the efﬁ  cacy 
and safety proﬁ  le, including the risk for cardiac toxicity, of 
NPLD in combination with cardiotoxic agents. Overall, the 
combination of conventional doxorubicin and trastuzumab 
results in signiﬁ  cantly greater cardiotoxicity than the same 
cumulative dose of conventional doxorubicin alone (Slamon 
et al 2001; Theodoulou et al 2002; Trigo et al 2002). How-
ever, until a randomized trial has been completed it will be 
difﬁ  cult to determine how the safety and efﬁ  cacy of NPLD 
plus trastuzumab compare with those of conventional doxo-
rubicin and trastuzumab.
NPLD: dose intensiﬁ  cation
The reduced cardiotoxicity from NPLD could lead to either 
prolonged duration of administration with higher cumula-
tive lifetime doses or reduced toxicity on dose escalation. 
In two studies that have addressed the latter, no evidence of 
clinical cardiotoxicity was observed (Moore et al 1998), but 
no added therapeutic beneﬁ  t to the dose escalation was seen 
(Shapiro et al 1999).International Journal of Nanomedicine 2007:2(4) 577
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Class IV PLD
Myocardial tissue was evaluated for evidence of anthracy-
cline-induced cardiac damage in 10 patients with AIDS-
related KS who had received PLD to cumulative doses of 
440 to 840 mg/m2, and blinded endomyocardial biopsy scores 
were compared with two control groups. PLD-treated patients 
had lower biopsy scores than conventional doxorubicin-
treated patients despite receiving higher cumulative doses of 
anthracycline. Median biopsy scores were 0.3 for PLD, 3.0 
for conventional doxorubicin control group 1 (p = 0.002 vs 
PLD), and 1.25 for conventional doxorubicin control group 
2 (p   0.001 vs PLD) (Berry et al 1998).
In another study of 5 AIDS patients, when the cumulative 
doses ranged from 1680 mg/m2 to 2360 mg/m2, LVEF on 
echocardiography fell below normal in only one patient, and 
this change was not correlated with clinical manifestations 
of a cardiomyopathy (Mustafa 2001).
PLD: cardiac function in studies
of solid tumors
In a retrospective analysis of 237 patients from 8 phase 
I/II trials of PLD therapy 42 reached or exceeded cumula-
tive doses of 500 mg/m2 (range, 500–1500 mg/m2); serial 
multiple-gated acquisition (MUGA) scans were available 
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Figure 2 Cumulative time to a cardiotoxicity endpoint, deﬁ  ned as a decrease in LVEF by more than 20 units to a value  50%, a decrease in LVEF by more than 10 units to a 
value  50%, or CHF. (A) Patients who received either NPLD alone or conventional doxorubicin alone (Dox) in a dose of 75 mg/m2 every 3 weeks. From Harris L, Batist G, 
Belt R, et al 2002. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as ﬁ  rst-line therapy of metastatic breast 
carcinoma. Cancer, 94:25–36. Copyright © 2002 American Cancer Society. This material is reproduced with permission of Wiley-Liss, Inc., a subsidiary of John Wiley and Sons, 
Inc. (B) Patients who received cyclophosphamide 600 mg/m2 every 3 weeks plus either NPLD (MC) or conventional doxorubicin (AC) in a dose of 60 mg/m2 every 3 weeks. 
Reprinted with permission from Batist G, Ramakrishnan G, Rao CS, et al 2001. Reduced cardiotoxicity and preserved antitumor efﬁ  cacy of liposome-encapsulated doxorubicin 
and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol, 19:1444–54. 
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for 41 patients: 5 (12%) had  10% decrease in LVEF, but 
no patient had clinical CHF secondary to cardiomyopathy 
(Safra et al 2000). Six patients, including 3 who had received 
conventional doxorubicin previously, underwent endomyo-
cardial biopsies after cumulative doses of 490–1320 mg/m2. 
In ﬁ  ve patients, Billingham endomyocardial biopsy scores 
ranged from 0 to 1, while the sixth had a score of 1.5 after 
both 900 and 1320 mg/m2 of PLD. Of the 195 patients who 
received cumulative PLD doses less than 500 mg/m2, one 
episode of CHF was recorded in a 70-year-old woman who 
had previously received chest irradiation and mitoxantrone 
exceeding a cumulative dose of 120 mg/m2.
Results of 10 endomyocardial biopsies in 8 patients 
treated with cumulative anthracycline doses greater than 
550 mg/m2, including more than 400 mg/m2 of PLD have 
been reported (Gabizon et al 2004). The median dose for 
cumulative anthracycline exposure was 908.5 mg/m2 (range, 
498–1680 mg/m2) and the median cumulative PLD dose 
was 707.5 mg/m2 (range, 490–1485 mg/m2). In spite of high 
cumulative doses of PLD and, in some cases, prior treatment 
with conventional doxorubicin, endomyocardial biopsy 
scores showed very limited damage relative to what would 
be expected from similar cumulative doses of conventional 
doxorubicin alone (Wolf 2001).
In retrospective studies of patients with  gynecologic 
cancers, maintenance PLD treatment in 18 patients with 
recurrent malignancy showed no clinical cardiac dysfunc-
tion; no changes in LVEF or symptomatic CHF were seen 
(Muggia et al 2004; Uyar et al 2004). Cardiac function was 
systematically evaluated as part of a pivotal randomized trial 
in which 474 patients with advanced ovarian cancer received 
either PLD 50 mg/m2 every 4 weeks or topotecan (Gordon 
et al 2001). No patient on either arm of the study developed 
CHF. At the time of the most recent report of results from 
this trial, 132 of the PLD-treated patients had both a base-
line and at least one subsequent LVEF assessment; 61 of 
these patients received cumulative PLD doses in excess of 
300 mg/m2 and 14 received more than 450 mg/m2 (highest 
cumulative dose = 1301 mg/m2) Three of the 61 patients 
showed a  20% absolute decrease in LVEF from baseline 
and three had at least one follow-up LVEF  45% (two of 
whom began the study with LVEF  45%). None of these 
patients showed clinical signs or symptoms of CHF and there 
was no evidence of a relationship between cumulative PLD 
dose and change from baseline LVEF.
In another randomized trial, 301 patients with metastatic 
breast cancer of whom 83% had received conventional anthra-
cyclines previously and 37% were considered resistant to 
anthracycline therapy were evaluated (Keller et al 2004). The 
lifetime cumulative dose of anthracycline exceeded 450 mg/m2 
in 34 patients and exceeded 600 mg/m2 in 14 patients on the 
PLD arm. Twenty-two of the PLD-treated patients met one 
or both criteria for LVEF change from baseline, but none of 
the patients developed signs or symptoms of CHF. Eight of 
these 22 patients had received a cumulative anthracycline dose 
 450 mg/m2 (pretreatment anthracycline plus PLD). Only one 
patient discontinued PLD treatment because of a decrease in 
LVEF, but it was not clear that this was related to PLD in part 
because the cumulative lifetime anthracycline dose was only 
199 mg/m2.
Cardiac toxicity from PLD has been compared with 
conventional doxorubicin in two randomized trials. A ran-
domized trial directly comparing PLD and conventional 
doxorubicin was attempted but discontinued early because 
of excessive cardiotoxicity in the conventional doxorubicin 
arm (Moore et al 1998). The overall response rates were 70% 
to conventional doxorubicin/paclitaxel and 69% to PLD/
paclitaxel. None of the patients who received PLD/paclitaxel 
had cardiotoxicity. Six of the 10 patients given conventional 
doxorubicin developed cardiotoxicity with reduction in 
LVEF from 60% at the end of the last cycle of chemotherapy 
to 10% 3 weeks later. Cardiac function remained abnormal 
for the remainder of the lives of 2 patients. Variable cardiac 
toxicity (grade 1–3) was noted in the other four patients. 
In another trial, 509 patients with metastatic breast cancer 
were randomly assigned to receive either PLD 50 mg/m2 
every 4 weeks or conventional doxorubicin 60 mg/m2 every 
3 weeks (O’Brien et al 2004). There were no signiﬁ  cant dif-
ferences in cardiac event-free survival between the PLD and 
conventional doxorubicin groups. However, 16% of patients 
continued PLD treatment for more than 9 months, compared 
with only 1% of patients receiving conventional doxorubicin. 
Ten patients (4%) on the PLD arm and 48 patients (19%) on 
the conventional doxorubicin arm developed cardiotoxicity. 
Of these patients, none on the PLD arm and 10 (4%) on 
the conventional doxorubicin arm had signs or symptoms 
of CHF. The likelihood of experiencing a cardiac event 
was 3.2 times greater on the conventional doxorubicin arm 
(p = 0.0006) (Figure 3). PLD was also signiﬁ  cantly less car-
diotoxic than conventional doxorubicin among patients who 
had received prior anthracycline treatment and those who 
had a cardiac risk factor at baseline. Despite the differences 
in dose and schedule of the two anthracycline formulations, 
this study suggested that patients can be treated for longer 
periods with PLD with less risk of cardiotoxicity and similar 
progression-free survival (O’Brien et al 2004).International Journal of Nanomedicine 2007:2(4) 579
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PLD in combination with other 
cardiotoxic drugs
Early results of clinical trials suggest that combining 
trastuzumab or a taxane with PLD significantly reduces 
cardiotoxicity risk without reducing chemotherapeutic 
efﬁ  cacy. In a nonrandomized trial by the Eastern Cooperative 
Oncology Group (ECOG 3198) the cardiac safety of PLD 
plus docetaxel, with or without trastuzumab, was evaluated 
in patients with HER2/neu-negative tumors and in patients 
with tumors that overexpressed HER2/neu. The addition of 
trastuzumab to PLD and docetaxel did not appear to increase 
the risk of cardiotoxicity as no cases of CHF were reported on 
either treatment arm. In a separate phase II trial in 30 patients 
with HER2-positive metastatic breast cancer (Chia et al 2006) 
receiving PLD 50 mg/m2 every 4 weeks and trastuzumab 
(4 mg/kg loading dose then 2 mg/kg weekly) only 3 patients 
experienced protocol-deﬁ  ned cardiotoxicity, all had received 
prior anthracyclines, but no patient had symptomatic CHF. 
However, demonstration that the combination of PLD with 
trastuzumab is safer than conventional doxorubicin plus 
trastuzumab must await completion of these ongoing studies.
Liposomal daunorubicin
Conﬂ  icting results emerged from clinical trials evaluating 
cardiac safety of liposomal daunorubicin. A randomized 
clinical trial of KS included 116 patients who received DNX 
40 mg/m2 every 2 weeks (Gill et al 1996) no cases of LVEF 
decline  20% was demonstrated on total of 115 repeat LVEF 
determinations. However, in a phase I study of patients with 
metastatic breast cancer, 1 in 5 patients experienced asymp-
tomatic cardiotoxicity with  15% decline in baseline LVEF 
at cumulative DNX doses of 800, 960, and 600 mg/m2 (plus 
300 mg/m2 of adjuvant conventional doxorubicin therapy) 
(O’Byrne et al 2002). In another study of 122 patients, 2 
patients who received DNX 150 mg/m2 (1 with a cumula-
tive dose of 900 mg/m2) experienced cardiotoxicity and 
died. During 6 months of follow-up in 14 patients, LVEF 
fell below 45% in one patient. The cardiotoxicity was more 
problematic with pediatric malignancies. In 14 children with 
recurrent or progressive brain tumor, DNX therapy (up to 
600 mg/m2 total) was associated with slight cardiotoxicity in 
three patients (21%) and a mean overall decrease of 13.8% 
in LVEF (Lippens 1999). A subsequent phase I study of 
48 children 1–18 years old was not completed because of 
evidence of cumulative cardiac toxicity (Lowis et al 2002). 
Thus while long-term cardiac safety studies with DNX are 
not available, in the short term cardiotoxicity may limit the 
usefulness of DNX.
Conclusion
Encapsulating conventional doxorubicin into pegylated 
liposomes has opened new avenues of study for improve-
ment of cancer treatment without a concomitant increase in 
toxicity. The liposomal components of PLD change the basic 
Figure 3 Cardiac event-free survival for PLD versus conventional doxorubicin in a randomized comparison of 509 patients with metastatic breast cancer. Cardiac event 
was deﬁ  ned as a decrease in LVEF by more than 20 units to a normal value, a decrease in LVEF by more than 10 units to an abnormal value, or CHF Patients received either 
PLD 50 mg/m2 every 4 weeks or conventional doxorubicin 60 mg/m2 every 3 weeks. The cumulative anthracycline dose included exposure before entry onto trial plus the 
total amount received during the course of the study. Adapted with permission from O’Brien ME, Wigler N, Inbar M, et al. 2004. Reduced cardiotoxicity and comparable 
efﬁ  cacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for ﬁ  rst-line treatment of metastatic breast cancer. Ann 
Oncol, 15:440–9. Copyright © 2004 Oxford University Press.
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pharmacology and pharmacokinetics of the conventional 
doxorubicin it encapsulates. These changes effectively allow 
PLD to travel to and concentrate in tumors without excess 
exposure of normal cells, thus raising the therapeutic index 
for conventional doxorubicin delivered in this manner. These 
attributes are reﬂ  ected in data from numerous preclinical 
studies, providing proof of principle that pegylated liposome-
encapsulated cytotoxic drugs, either alone or as part of 
combination therapy, have a variety of potential applications 
in the treatment of cancers. The limited available clinical 
evidence suggests that liposomal anthracyclines can be used 
in place of conventional anthracyclines to reduce the risk of 
cardiotoxicity without reducing the efﬁ  cacy of therapy in the 
treatment of some malignancies. Further results are eagerly 
awaited from ongoing controlled trials of cardiac safety with 
long-term liposomal anthracycline therapy, either alone or 
in combination with cardiotoxic agents.
Similarly, future developments in the rapidly evolving 
ﬁ  eld of pharmacogenomics are likely to permit oncologists 
to tailor therapy to optimize therapeutic effectiveness, 
while minimizing toxicity. There are genuine reasons 
to be enthusiastic. Further, it can be anticipated that our 
growing understanding of the critical role of speciﬁ  c 
molecular events in individual cancers will permit 
the development of prognostic and, most importantly, 
predictive biomarkers, which will aid in the selection of 
optimal management strategies for individual patients. In 
addition, it is important to continue to aggressively explore 
innovative methods of using established cytotoxic agents 
such as regional treatment, maintenance therapy, weekly/
daily delivery schedules, and concurrent chemotherapy-
radiation therapy.
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